Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters-Reference-Cited by-同舟云学术

Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters

Published:2015-06-11 Issue:6 Volume:20 Page:515-519
ISSN:1092-8529
Container-title:CNS Spectrums
language:en
Short-container-title:CNS Spectr.

Author:

Stahl Stephen M.

Abstract

Vortioxetine is an antidepressant with multiple pharmacologic modes of action that enhance release of dopamine, norepinephrine, acetylcholine, and histamine.

Publisher

Cambridge University Press (CUP)

Subject

Psychiatry and Mental health,Neurology (clinical)

Reference29 articles.

1. Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders

2. Role of 5-HT1Aautoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies

3. Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

4. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists

5. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin’s downstream effects on glutamate and GABA (gamma-amino-butyric acid) release by blocking 5HT3 and 5HT7 receptors;Stahl;CNS Spectr

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurochemistry of the Central Nervous System;From Anatomy to Function of the Central Nervous System;2025

2. Vortioxetine improved schizophrenia‐like behavioral deficits in a Poly I:C‐induced maternal immune activation model of schizophrenia in rats;Fundamental & Clinical Pharmacology;2024-07-04

3. Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study;Neuropsychiatric Disease and Treatment;2024-07

4. Association between NTRK2 Polymorphisms, Hippocampal Volumes and Treatment Resistance in Major Depressive Disorder;Genes;2023-11-03

5. Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review;Medicina;2023-08-12